Enregistrement de source primaire
La FDA a accepté le supplément d'approbation préalable visant à étendre la tranche d'âge indiquée pour KHINDIVI afin d'inclure les enfants de moins de cinq ans. Une date cible d'action PDUFA du 28 mai 2027 a été assignée. En cas d'approbation, Eton anticipe un lancement commercial peu de temps après.
EX-99.1 2 eton-2026q332026xexx991.htm EX-99.1 Document Exhibit 99.1 Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results • Record Q3 2026 product sales of $57.9 million, 158% year-over-year growth; surpassed $200 million annualized revenue run rate goal five quarters ahead of schedule • Q3 2026 fully diluted GAAP EPS of $1.06, non-GAAP fully diluted EPS of $0.50; EBITDA of $24.8 million, Adjusted EBITDA of $28.5 million or 49% of revenue • Raised 2026 revenue guidance to more than $175 million, from prior guidance of more than $145 million; raised 2026 Adjusted EBITDA to more than 40%, from prior guidance of more than 35% • Management to hold conference call today at 4:30pm ET DEER PARK, Ill., November 5, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Co
hydrocortisone · étiquette FDA mise à jour (effective 20251215)